Sveriges mest populära poddar
Oncology Today with Dr Neil Love
Hälsa och motionMedicin

Striving for Consensus: Current and Future Management of Metastatic Non-Small Cell Lung Cancer in Patients Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy

2 tim 44 min•8 september 2023

Dr Corey Langer, Dr Ticiana Leal, Dr Karen Reckamp and Dr Jacob Sands discuss the optimal current management of relapsed NSCLC and provide perspectives on the future of care for patients with this disease, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here

Fler avsnitt av Oncology Today with Dr Neil Love

Visa alla avsnitt av Oncology Today with Dr Neil Love
Oral SERDs for Breast Cancer — Year in Review Series on Relevant New Datasets and Advances
•57 min
EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
•57 min
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
•17 min
Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances
•58 min
Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances
•59 min
Lung Cancer — 5-Minute Journal Club with Dr Natalie Vokes: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
•27 min
HR-Positive Metastatic Breast Cancer — An Interview with Dr Seth Wander on Optimizing Biomarker Assessment and Related Treatment Decision-Making
•1 tim
Metastatic Bladder Cancer — Rapid Case Review Issue 4
•28 min
ER-Positive, HER2-Positive Metastatic Breast Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy
•58 min
Localized Colorectal Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
•15 min

Oncology Today with Dr Neil Love med Dr. Neil Love finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.